Giuliana Salvatore

List of Publications by Year
in descending order

48 papers	4,556 citations	201385 27 h-index	223531 46 g-index
48 all docs	48 docs citations	48 times ranked	4424 citing authors

#	Article	IF	Citations
1	BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5399-5404.	1.8	950
2	BAY 43-9006 Inhibition of Oncogenic RET Mutants. Journal of the National Cancer Institute, 2006, 98, 326-334.	3.0	458
3	Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer. Cancer Research, 2005, 65, 10199-10207.	0.4	319
4	Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5175-5180.	1.8	252
5	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	231
6	RET/Papillary Thyroid Cancer Rearrangement in Nonneoplastic Thyrocytes: Follicular Cells of Hashimotoâ€™s Thyroiditis Share Low-Level Recombination Events with a Subset of Papillary Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2414-2423.	1.8	175
7	BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4267-4271.	1.8	171
8	A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma. Cancer Research, 2007, 67, 10148-10158.	0.4	167
9	BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma. Clinical Cancer Research, 2006, 12, 1623-1629.	3.2	160
10	Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2004, 209, 1-6.	3.2	152
11	Heterogeneity in the Distribution ofRET/PTCRearrangements within Individual Post-Chernobyl Papillary Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4272-4279.	1.8	127
12	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	126
13	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. American Journal of Pathology, 2002, 160, 247-254.	1.9	103
14	Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer. Cancer Research, 2007, 67, 11821-11829.	0.4	100
15	The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3511-3516.	1.8	93
16	Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 450-455.	1.8	90
17	Molecular profile of hyalinizing trabecular tumours of the thyroid: High prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. European Journal of Cancer, 2005, 41, 816-821.	1.3	87
18	Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5270-5278.	1.8	71

#	Article	IF	Citations
19	Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood, 2004, 103, 2718-2726.	0.6	64
20	Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma. Thyroid, 2007, 17, 381-388.	2.4	64
21	YAP1acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. Oncotarget, 2014, 5, 2608-2621.	0.8	62
22	Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma. Cancer Research, 2009, 69, 1916-1923.	0.4	60
23	Receptor tyrosine kinase inhibitors in thyroid cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 1023-1038.	2.2	39
24	TWIST1 Plays a Pleiotropic Role in Determining the Anaplastic Thyroid Cancer Phenotype. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E772-E781.	1.8	39
25	Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4703-4709.	1.8	38
26	FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocrine-Related Cancer, 2012, 19, 695-710.	1.6	36
27	Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer. Endocrine-Related Cancer, 2010, 17, 785-796.	1.6	34
28	TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells. Oncotarget, 2016, 7, 70575-70588.	0.8	28
29	miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA. Endocrine, 2019, 65, 582-594.	1.1	26
30	Identification of Targets of Twist1 Transcription Factor in Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1617-E1626.	1.8	23
31	Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. Endocrine-Related Cancer, 2012, 19, 409-421.	1.6	22
32	Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells. Molecular Cancer, 2014, 13, 160.	7.9	22
33	Morphological Ultrasound Microimaging of Thyroid in Living Mice. Endocrinology, 2009, 150, 4810-4815.	1.4	21
34	miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase. British Journal of Cancer, 2020, 123, 426-437.	2.9	20
35	Junctional adhesion moleculeâ€A is downâ€regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 Î±/Î² pathways. Molecular Carcinogenesis, 2019, 58, 1181-1193.	1.3	19
36	Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. BMC Medical Imaging, 2013, 13, 31.	1.4	17

#	Article	IF	Citations
37	Adiponectin and leptin exert antagonizing effects on proliferation and motility of papillary thyroid cancer cell lines. Journal of Physiology and Biochemistry, 2021, 77, 237-248.	1.3	16
38	The TUSC2 Tumour Suppressor Inhibits the Malignant Phenotype of Human Thyroid Cancer Cells via SMAC/DIABLO Protein. International Journal of Molecular Sciences, 2020, 21, 702.	1.8	15
39	Different mutations of the RET gene cause different human tumoral diseases. Biochimie, 1999, 81, 397-402.	1.3	12
40	High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid Carcinoma. Thyroid, 2016, 26, 552-558.	2.4	12
41	Multimodal imaging for a theranostic approach in a murine model of B-cell lymphoma with engineered nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 483-491.	1.7	11
42	Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential. , 0, .		7
43	Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer. International Journal of Molecular Sciences, 2017, 18, 2731.	1.8	5
44	Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2005, 230, 149-150.	3.2	4
45	Anaplastic Thyroid Carcinoma: Molecular Tools for Diagnosis and Therapy. International Journal of Endocrinology, 2015, 2015, 1-2.	0.6	3
46	Effects of Annurca Flesh Apple Polyphenols in Human Thyroid Cancer Cell Lines. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.	1.9	3
47	Pros and Cons of Cellular Studies in Developing New Drugs for Thyroid Cancers. Thyroid, 2008, 18, 819-822.	2.4	2
48	Abstract 3869: Allelic loss of a specific 3p segment: A key target loci involved in the development of highly malignant thyroid cancer histotypes. , 2011, , .		0